glp-1 news oct 9 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Market Trends and Global

The results suggested that while both medications were associated with weight loss and improved glycemic outcomes, the cost-effectiveness ratio of Tirzepatide was more favorable

Retrospective EHR-based studies can capture real-world associations, yet they are especially vulnerable to residual confounding, treatment-selection bias, differences in healthcare engagement, and unmeasured disease biology

"I'm not going to, but I could weep right now for all of the many days and nights I've journaled about this being my fault and why can't I conquer this thing?" Winfrey told host Jane Pauley

We advocate for diabetes patients needing access to programs calculating medication costs using financial circumstances rather than insurance formulary tiers

10.2337/diabetes.51.4.943 31

Pillars 12, 100127